J Cereb Blood Flow Metab 29, 1924-1932. Wei HH, Lu XC, Shear DA, Waghray A, Yao C, Tortella FC, Dave JR (2009) NNZ-2566 cure inhibits neuroinflammation and pro-inflammatory cytokine expression induced by experimental penetrating ballistic-like mind personal injury in rats. J Neurol Sci 278, 85-90. Lu XC, Chen RW, Yao C, Wei H, Yang X, Liao Z, Dave JR, Tortella FC (2009) NNZ-2566, a glypromate analog, increases functional recovery and attenuates apoptosis and swelling in a rat design of penetrating ballistic-kind mind personal injury. Drugs Today (Barc)48 Suppl A, 63-69. Leker RR, Teichner A, Grigoriadis N, Ovadia H, Brenneman DE, Fridkin M, Giladi E, Romano J, Gozes I (2002) NAP, a femtomolar-acting peptide, protects the mind versus ischemic harm by cutting down apoptotic loss of life. Neurosci Lett 361, 128-131. Gozes I, Zaltzman R, Hauser J, Brenneman DE, Shohami E, Hill JM (2005) The expression of exercise-dependent neuroprotective protein (ADNP) is controlled by mind damage and therapy of mice with the ADNP derived peptide, NAP, minimizes the severity of traumatic head harm. Peptides 24, 1413-1423. Alcalay RN, Giladi E, Pick CG, Gozes I (2004) Intranasal administration of NAP, a neuroprotective peptide, decreases panic-like behavior in getting older mice in the elevated additionally maze.
Matsuoka Y, Gray AJ, Hirata-Fukae C, Minami SS, Waterhouse EG, Mattson MP, LaFerla FM, Gozes I, Aisen PS (2007) Intranasal NAP administration lessens accumulation of amyloid peptide and tau hyperphosphorylation in a transgenic mouse model of Alzheimer’s condition at early pathological stage. Curr Alzheimer Res 4, 550-552. Tobinick EL, Gross H (2008) Rapid enhancement in verbal fluency and aphasia pursuing perispinal etanercept in Alzheimer’s illness. Curr Alzheimer Res 2, 149-153. W. Froestl et al. J Neuroinflammation 5, two. Griffin WS (2008) Perispinal etanercept: Potential as an Alzheimer therapeutic. Curr Alzheimer Res 6, 455-460. Geerts H (2008) AL-108 and AL-208, formulations of the neuroprotective NAP fragment of action-dependent neuroprotective protein, for cognitive conditions. Curr Alzheimer Res 8, 583-591. Anton Alvarez X, Fuentes P (2011) Cerebrolysin in Alzheimer’s sickness. CNS Drug Rev 11, 353-368. Gozes I, Stewart A, ashlyndiamond-chaturbate Morimoto B, Fox A, Sutherland K, Schmeche D (2009) Addressing Alzheimer’s disorder tangles: From NAP to AL-108. CNS Drugs 24, 263-266. Bajenaru O, Tiu C, Moessler H, Antochi F, Muresanu D, Popescu BO, Novak P (2010) Efficacy and protection of Cerebrolysin in individuals with hemorrhagic stroke. J Med Life 3, 137-143. Guekht AB, Moessler H, Novak PH, Gusev EI (2011) Cerebrolysin in vascular dementia: Improvement of scientific outcome in a randomized, double-blind, placebocontrolled multicenter demo.
J Neurol Sci 267, 112-119. Muresanu DF, Alvarez XA, Moessler H, Novak PH, Stan A, Buzoianu A, Bajenaru O, Popescu BO (2010) Persistence of the effects of Cerebrolysin on cognition and qEEG slowing in vascular dementia sufferers: Results of a 3-month extension analyze. Stroke 35, 1738-1743. Suckfuell M, Canis M, Strieth S, Scherer H, Haisch A (2007) Intratympanic cure of acute acoustic trauma with a mobile-permeable JNK ligand: A future randomized section I/II research. Eur J Neurol 18, 59-68. Muresanu DF, Alvarez XA, Moessler H, Buia M, Stan A, Pintea D, Moldovan F, Popescu BO (2008) A pilot study to consider the results of Cerebrolysin on cognition and qEEG in vascular dementia: Cognitive enhancement correlates with qEEG acceleration. Eur J Pharmacol 579, 1-12. Tracey D, Klareskog L, Sasso EH, Salfeld JG, Tak PP (2008) Tumor necrosis element antagonist mechanisms of motion: A thorough review. Curr Alzheimer Res 3, 197-199. Gozes I, Steingart RA, Spier Ad (2004) NAP mechanisms of neuroprotection.
Pharmacol Ther 114, 146-154. Gozes I (2011) NAP (davunetide) provides practical and structural neuroprotection. Curr Alzheimer Res 4, 507-509. Merenlender-Wagner A, Pikman R, Giladi E, Andrieux A, Gozes I (2010) NAP (davunetide) improves cognitive actions in the Stop heterozygous mouse-a microtubuledeficient model of schizophrenia. Curr Pharm Des 17, 2603-2612. Javitt DC, Buchanan RW, Keefe RS, Kern R, McMahon RP, Green MF, Lieberman J, Goff DC, Csernansky JG, McEvoy JP, Jarskog F, Seidman LJ, Gold JM, Kimhy D, Nolan KS, Barch DS, Ball MP, Robinson J, Marder SR (2012) Effect of the neuroprotective peptide davunetide (AL-108) on cognition and useful potential in schizophrenia. Curr Pharm Des 17, 10401044. Gozes I (2011) Microtubules, schizophrenia and cognitive habits: Preclinical growth of davunetide (NAP) as a peptide-drug applicant. Curr Pharm Des 17, 3413-3417. Gozes I, Spivak-Pohis I (2006) Neurotrophic consequences of the peptide NAP: A novel neuroprotective drug candidate. Mol Cell Neurosci 46, 597-606. Gozes I (2007) Activity-dependent neuroprotective protein: From gene to drug applicant. 83 Shiryaev N, Pikman R, Giladi E, Gozes I (2011) Protection against tauopathy by the drug candidates NAP (davunetide) and D-SAL: Biochemical, cellular and behavioral features. J Pharmacol Exp Ther 325, 146-153. Shiryaev N, Jouroukhin Y, Giladi E, Polyzoidou E, Grigoriadis NC, Rosenmann H, Gozes I (2009) NAP guards memory, boosts soluble tau and lessens tau hyperphosphorylation in a tauopathy design.